The CREG1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblastoid cell line, in which the gene encoding CREG1 (Cellular Repressor of E1A-stimulated Genes 1) has been disrupted via CRISPR/Cas9-mediated gene targeting. This polyclonal knockout pool provides a loss-of-function model for studying the tumor-suppressive and differentiation-promoting functions of CREG1 in a B-cell lymphoma background.
The Raji host cell line, originally isolated from a patient with Burkitt??s lymphoma, represents an Epstein?CBarr virus (EBV)-positive B-cell model that retains key features of aggressive B-cell malignancies. Raji cells are widely used for investigating oncogenic mechanisms, viral pathogenesis, and therapeutic responses in B-cell lymphoma research.
CREG1 encodes a secreted glycoprotein that acts as a transcriptional repressor and negatively regulates cell proliferation. Mechanistically, CREG1 antagonizes E1A-mediated transformation by interacting with Rb and p300/CBP, thereby inhibiting E2F1-driven transcription of cell cycle genes such as cyclin A and cdc2. Additionally, CREG1 promotes lysosomal biogenesis by upregulating LAMP1 and cathepsins, and it enhances cellular differentiation. Upstream, CREG1 expression is modulated by p53, E2F1, MEF2 transcription factors, TGF-??, and insulin, while downstream it influences ??-catenin stabilization and insulin receptor substrate (IRS) signaling. CREG1 also binds to the mannose-6-phosphate/IGF2 receptor (IGF2R), linking its function to lysosomal enzyme trafficking.
In the context of Raji cells, disruption of CREG1 eliminates its growth-inhibitory and pro-differentiation activities, potentially accelerating cell-cycle progression and attenuating lysosomal function. This knockout model is particularly relevant for dissecting the role of CREG1 in B-cell lymphoma pathogenesis, as loss of CREG1 expression has been associated with enhanced proliferation and impaired differentiation in various cancers. Furthermore, the EBV-driven background of Raji cells provides a platform to study the interplay between viral oncoproteins and host tumor suppressors such as CREG1.
The CREG1 Knockout Raji Polyclonal Cells are suitable for a range of research applications, including investigation of tumor suppressor mechanisms, lysosomal biogenesis, and B-cell lymphoma biology. Researchers can employ this model in proliferation and apoptosis assays, flow cytometric cell cycle analysis, RT-qPCR and Western blotting for E2F target genes and lysosomal markers (e.g., LAMP1, cathepsin D), co-immunoprecipitation of CREG1-interacting partners (such as Rb or p300/CBP), and reporter assays to assess ??-catenin/TCF or E2F activity. Additionally, the cells can be used in drug sensitivity screens and oncogene cooperation studies to evaluate genetic interactions relevant to lymphoma. For further information, please contact Ascent Research.
